Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with low and intermediate risk of myelodysplastic syndrome (MDS).
Myelodysplastic Syndromes
DRUG: TEW-7197
Maximum Tolerated Dose (MTD) for dose escalation phase, To define the MTD and determine RP2D, 4 weeks|Hematologic improvement (HI), To evaluate the best hematologic improvement (HI) based on IWG 2006 criteria, At 2, 4, 8, 12 and 16 weeks of treatment
Hematologic Improvement (HI), To evaluate the duration of HI, At 2, 4, 8, 12 and 16 weeks of treatment|Red blood cell transfusion independency, To evaluate rate and duration of Red blood cell transfusion independency, At 2, 4, 8, 12 and 16 weeks of treatment|Bone marrow response and cytogenetic response, To evaluate the frequency of bone marrow response (CP+PR) and cytogenetic response, At 2, 4, 8, 12 and 16 weeks of treatment|Time to progression, Time to progression to higher risk or acute myeloid leukemia, At 2, 4, 8, 12 and 16 weeks of treatment|Relationship between mutations and response, To evaluate the relationship between mutations and response, At 2, 4, 8, 12 and 16 weeks of treatment|Relationship between various stem and progenitor alterations and response, To evaluate the relation ship between various stem and progenitor alterations and response, At 2, 4, 8, 12 and 16 weeks of treatment|Quality of life with MDS, To evaluate the quality of life parameters experienced by patients with MDS, At 4, 8, 12 and 16 weeks of treatment|Biomarker, Determine pharmacodynamic markers in bone marrow, At 4, 8, 12 and 16 weeks of treatment
This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with low and intermediate risk of myelodysplastic syndrome (MDS).